Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan Officially Drops Japanese PI Requirement before Global Trial Entry
December 26, 2023
- Japan Filing within 3 Months of Global Submission Eligible for Sakigake: MHLW
December 26, 2023
- Japan Ends Supply of Takeda/Novavax’s COVID Jab, 7.14 Million Doses Discarded
December 26, 2023
- Kaigen Pharma Hit by Suspension Order for Decades of Illicit Manufacturing
December 25, 2023
- MHLW Budget Hits Record High at 33.8 Trillion Yen, Ups Funding for Drug Innovation
December 25, 2023
- (Update) Sawai Slapped with Biz Improvement Order over Rigged Quality Tests
December 25, 2023
- MHLW Announces “Innovation Box” Tax Regime: FY2024 Reform
December 25, 2023
- Japan Approves Label Expansions for Rexulti, Rituxan, and More
December 25, 2023
- Japan Grants Orphan Tags to Keytruda, Teprotumumab, and 3 More Drugs
December 25, 2023
- Ryukaikon OKs Revised Distribution Guidelines, Pharmas Urged to Explain Rationale of Solo Wholesaler Policy
December 22, 2023
- Japan Aims for 80% Unit-Price Negotiation Rate by FY2026-End: Reform Timeline
December 22, 2023
- Chuikyo OKs Outline of FY2024 Drug Pricing Reform; No Unprofitability Re-Pricing for 7%-Plus Price Gap
December 21, 2023
- Health Ministry Panel OKs Inclusion of 5-in-1 Jab in NIP from Next April
December 21, 2023
- Japan to Roll Out New LLP Coverage Rule in October; 18 Billion Yen Saving Eyed for FY2024
December 21, 2023
- Masaki Ogushi Promoted to Chief of LDP’s Health Division
December 21, 2023
- Japan to Cut Drug Prices by 0.97% on Healthcare Cost Basis in FY2024
December 20, 2023
- Gist of FY2024 Drug Pricing Reform
December 20, 2023
- MHLW to Post Medical Facilities Providing Leqembi Treatment on Website
December 18, 2023
- Japan to Raise Medical Fee by 0.88%, Cut Drug Costs by Around 1% in FY2024
December 18, 2023
- Chuikyo Split on Copay Rate under Elective Care Scheme; Political Decision Likely over 1/2 or 1/4
December 18, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…